Ratnakar Securities

Mobile Trading
COMPANY
more from company profile
HomeMarket Info Company Profile Smart Quotes

Smart Quotes

ALIVUS LIFE SCIENCES LTD.

NSE : ALIVUSBSE : 543322ISIN CODE : INE03Q201024Industry : Pharmaceuticals & DrugsHouse : Glenmark
BSE937.353.25 (+0.35 %)
PREV CLOSE ( ) 934.10
OPEN PRICE ( ) 928.45
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 1649
TODAY'S LOW / HIGH ( )928.45 945.50
52 WK LOW / HIGH ( )827.1 1335
BSE
1D 1M 3M 1Y 3Y 5Y
STOCK SUMMARY
Incorporation Year : 23-06 2011
Management Info
Hiren K Patel - Chairman Yasir Rawjee - Managing Director
Registered Office

Address Plot No. 170-172,Chandramouli Industrial Estate,Mohol Bazarpeth,
Solapur,
Maharashtra-413213

Phone 02189 234456/234246

Email complianceofficer@alivus.com

Website www.alivus.com

Registrars Details
K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.)
Karvy Selenium Tower B, Plot 31-32,Gachibowli,Financial District,Nanakramguda,Hyderabad
 Listing : BSE, NSE
NEWS
12Aug Alivus Life Sciences informs about new
Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosur..
11Aug Alivus Life Sciences submits intimatio
Alivus Life Sciences has informed that the Fourteenth (14th) Annual Gene..
28Jul USFDA issues EIR with NAI classificati
The United States Food and Drug Administration (USFDA) has issued an Est..
09Jun Alivus Life Sciences informs about ana
Alivus Life Sciences has informed that pursuant to Regulation 30 and Par..
04Apr USFDA issues EIR with Voluntary Action
The United States Food and Drug Administration (USFDA) has issued an Est..
MORE
Financials
in Millions
QTR Jun 25 ANNUAL 25
Net Profit1215.354856.27
Gross Profit 1629.81 6541.31
Operating Profit 1812.967171.54
Net Sales 6018.4623868.84
MORE
ROLLING FORWARD P/E (EOD)
EVENT CALENDAR
peer group
Neuland Laboratories (BSE)
up  14355.70 (4.70%)
M.Cap ( in Cr)18418.20
Abbott India (BSE)
up  32605.90 (0.77%)
M.Cap ( in Cr)69285.26
Astrazeneca Pharma I (BSE)
up  9084.30 (1.64%)
M.Cap ( in Cr)22710.75
Glenmark Pharma (BSE)
up  2005.20 (4.51%)
M.Cap ( in Cr)56586.91
Ajanta Pharma (BSE)
up  2556.10 (3.12%)
M.Cap ( in Cr)31934.79
MORE
Shareholding Pattern
PROMOTERS 74.94%
MUTUAL FUNDS/UTI 4.06%
NON-INSTITUTION 13.03%
FI/BANKS/INSURANCE 0.18%
GOVERNMENT 0%
FII 0%
MORE
Mf Holdings
MORE
FAQs
079-49005200 / 01 / 02
info@ratnakarsecurities.com
Download Mobile App

Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020.

Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge.

Pay 20% upfront margin of the transaction value to trade in cash market segment.

Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard.

Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month.
.......... Issued in the interest of Investors

INVESTOR CHARTER
products
about us
usefull links
news room

Ratnakar Securities Pvt. Ltd. : SEBI Registration No. of NSE, BSE : INZ000191735 | SEBI Registration No. of NSDL : IN-DP-NSDL-66-88
Ratnakar Commodities Pvt. Ltd : SEBI Registration No. of MCX : INZ000024138
Investor Grievance ID : investorgrievance@ratnakarsecurities.com
Online Dispute Resolution Portal - SMART ODR
To File A Complaint on SCORES Click Here
For Nomination, Please Click Here
To Close Account, Please Click Here
© 2018 Ratnakar Securities Pvt. Ltd. All rights reserved.
Designed, Developed & Content Powered by ●●● Accord Fintech Pvt. Ltd.
CLOSE X

Filing complaints on SCORES Easy & quick

  • > Register on SCORES portal (link:https://scores.gov.in)
  • > Mandatory details for filing complaints on SCORES
    • Name
    • PAN
    • Address
    • Mobile Number
    • E-mail ID
  • > Benefits:
    • Effective communication
    • Speedy redressal of the grievances
CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source: SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.